ECOG-ACRIN EA5181

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Objective

This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small-cell lung cancer that cannot be removed by surgery (unresectable).

NCT#04092283

Clinical Trial Categories

• Lung Cancer

Contact

NH Oncology Hematology Clinical Research Dept. at (603) 224-2556